{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T07:50:17Z","timestamp":1726213817459},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s11892-007-0060-0","type":"journal-article","created":{"date-parts":[[2007,10,3]],"date-time":"2007-10-03T07:13:29Z","timestamp":1191395609000},"page":"369-375","source":"Crossref","is-referenced-by-count":5,"title":["Exenatide and rimonabant: New treatments that may be useful in the management of diabetes and obesity"],"prefix":"10.1007","volume":"7","author":[{"given":"Jennifer B.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark N.","family":"Feinglos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,4]]},"reference":[{"key":"60_CR1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(05)60426-6","volume":"352","author":"R. Turner","year":"1998","unstructured":"Turner R: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998, 352:837\u2013853.","journal-title":"Lancet"},{"key":"60_CR2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jama.291.3.335","volume":"291","author":"S.H. Saydah","year":"2004","unstructured":"Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335\u2013342.","journal-title":"JAMA"},{"key":"60_CR3","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/sj.ijo.0803015","volume":"29","author":"C.C. Curioni","year":"2005","unstructured":"Curioni CC, Lourenco PM: Long-term weight loss after diet and exercise\u2014a systematic review. Int J Obes 2005, 29:1168\u20131174.","journal-title":"Int J Obes"},{"key":"60_CR4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","volume":"63","author":"M.A. Nauck","year":"1986","unstructured":"Nauck MA, Homberger F, Siegel EG, et al.: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986, 63:492\u2013498.","journal-title":"J Clin Endocrinol Metab"},{"key":"60_CR5","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/01.smj.0000240730.86237.b6","volume":"99","author":"N. Mikhail","year":"2006","unstructured":"Mikhail N: Exenatide: a novel approach for treatment of type 2 diabetes. South Med J 2006, 99:1271\u20131280.","journal-title":"South Med J"},{"key":"60_CR6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.atherosclerosissup.2006.01.007","volume":"7","author":"H. Lebovitz","year":"2005","unstructured":"Lebovitz H: Diabetes: assessing the pipeline. Atheroscler Suppl 2005, 7:43\u201349.","journal-title":"Atheroscler Suppl"},{"key":"60_CR7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-005-0107-1","volume":"49","author":"J.J. Holst","year":"2005","unstructured":"Holst JJ: Glucagon-like peptide-1: from extract to agent. Diabetologia 2005, 49:253\u2013260.","journal-title":"Diabetologia"},{"key":"60_CR8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.regpep.2004.07.014","volume":"128","author":"M.A. Nauck","year":"2005","unstructured":"Nauck MA, Meier JJ: Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005, 128:135\u2013148.","journal-title":"Regul Pept"},{"key":"60_CR9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"D.J. Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696\u20131705.","journal-title":"Lancet"},{"key":"60_CR10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M. Zander","year":"2002","unstructured":"Zander M, Madsbad S, Madsen JL, et al.: Effect of 6-week course of glucagons-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824\u2013830.","journal-title":"Lancet"},{"key":"60_CR11","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1007\/s00125-005-1878-0","volume":"48","author":"B.E. Dunning","year":"2005","unstructured":"Dunning BE, Foley JE, Ahren B: Alpha cell function in health and disease: influence of glucagons-like peptide-1. Diabetologia 2005, 48:1700\u20131713.","journal-title":"Diabetologia"},{"key":"60_CR12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/dia.2006.8.385","volume":"8","author":"D.M. Kendall","year":"2006","unstructured":"Kendall DM, Kim D, Maggs D: Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 2006, 8:385\u2013396.","journal-title":"Diabetes Technol Ther"},{"key":"60_CR13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3122\/jabfm.19.6.612","volume":"19","author":"D. Hinnen","year":"2006","unstructured":"Hinnen D, Nielsen LL, Waninger A, et al.: Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. J Am Board Fam Med 2006, 19:612\u2013620.","journal-title":"J Am Board Fam Med"},{"key":"60_CR14","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2165\/00003495-200565120-00008","volume":"65","author":"G.M. Keating","year":"2005","unstructured":"Keating GM: Exenatide. Drugs 2005, 65:1681\u20131692.","journal-title":"Drugs"},{"key":"60_CR15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/vhrm.2006.2.1.69","volume":"2","author":"C.A. Schnabel","year":"2006","unstructured":"Schnabel CA, Wintle M, Kolterman O: Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag 2006, 2:69\u201377.","journal-title":"Vasc Health Risk Manag"},{"key":"60_CR16","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1210\/jc.2005-1093","volume":"90","author":"F. Fehse","year":"2005","unstructured":"Fehse F, Trautmann M, Holst JJ, et al.: Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005, 90:5991\u20135997.","journal-title":"J Clin Endocrinol Metab"},{"key":"60_CR17","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","volume":"27","author":"J.B. Buse","year":"2004","unstructured":"Buse JB, Fineman MS, Henry RR: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628\u20132635.","journal-title":"Diabetes Care"},{"key":"60_CR18","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"R.A. DeFronzo","year":"2005","unstructured":"DeFronzo RA, Kim DD, Ratner RE: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092\u20131100.","journal-title":"Diabetes Care"},{"key":"60_CR19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","volume":"28","author":"D.M. Kendall","year":"2005","unstructured":"Kendall DM, Kim DD, Riddle MC: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083\u20131091.","journal-title":"Diabetes Care"},{"key":"60_CR20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1463-1326.2006.00602.x","volume":"8","author":"L. Blonde","year":"2006","unstructured":"Blonde L, Klein EJ, Han J, et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436\u2013447.","journal-title":"Diabetes Obes Metab"},{"key":"60_CR21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1463-1326.2006.00589.x","volume":"8","author":"R.E. Ratner","year":"2006","unstructured":"Ratner RE, Maggs D, Nielsen LL, et al.: Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419\u2013428.","journal-title":"Diabetes Obes Metab"},{"key":"60_CR22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/dmrr.646","volume":"22","author":"M.C. Riddle","year":"2006","unstructured":"Riddle MC, Henry RR, Poon TH, et al.: Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 2006, 22:483\u2013491.","journal-title":"Diabetes Metab Res Rev"},{"key":"60_CR23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clinthera.2007.01.015","volume":"29","author":"J.B. Buse","year":"2007","unstructured":"Buse JB, Klonoff DC, Nielsen LL, et al.: Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007, 29:139\u2013153.","journal-title":"Clin Ther"},{"key":"60_CR24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-146-7-200704030-00003","volume":"146","author":"B. Zinman","year":"2007","unstructured":"Zinman B, Hoogwerf BJ, Duran Garcia S, et al.: The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007, 146:477\u2013485.","journal-title":"Ann Intern Med"},{"key":"60_CR25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","volume":"143","author":"R.J. Heine","year":"2005","unstructured":"Heine RJ, Van Gaal LF, Johns D, et al.: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005, 143:559\u2013569.","journal-title":"Ann Intern Med"},{"key":"60_CR26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","volume":"50","author":"M.A. Nauck","year":"2007","unstructured":"Nauck MA, Duran S, Kim D, et al.: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with a sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259\u2013267.","journal-title":"Diabetologia"},{"key":"60_CR27","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1345\/aph.1H060","volume":"40","author":"B.K. Yoo","year":"2006","unstructured":"Yoo BK: Exenatide: a new option for the treatment of type 2 diabetes. Ann Pharmacother 2006, 40:1777\u20131784.","journal-title":"Ann Pharmacother"},{"key":"60_CR28","unstructured":"Amylin Pharmaceuticals: Exenatide prescribing information. http:\/\/www.BYETTA.com\/index.jsp . Accessed May 14, 2007."},{"key":"60_CR29","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1478-3231.2006.01315.x","volume":"26","author":"M.E. Tushuizen","year":"2006","unstructured":"Tushuizen ME, Bunck ME, Pouwels MC, et al.: Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006, 26:1015\u20131017.","journal-title":"Liver Int"},{"key":"60_CR30","first-page":"116","volume":"55","author":"D. Kim","year":"2006","unstructured":"Kim D, MacConnell L, Zhuang D, et al.: Safety and efficacy of a once-weekly, long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes (abstract 487-P). Diabetes 2006, 55:116.","journal-title":"Diabetes"},{"key":"60_CR31","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1038\/sj.ijo.0803278","volume":"30","author":"J.P. Despres","year":"2006","unstructured":"Despres JP, Lemieux I, Almeras N: Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes 2006, 30:S44\u2013S52.","journal-title":"Int J Obes"},{"key":"60_CR32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1527-3458.2006.00091.x","volume":"12","author":"M.A.M. Carai","year":"2006","unstructured":"Carai MAM, Colombo G, Maccioni P, et al.: Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 2006, 12:91\u201399.","journal-title":"CNS Drug Rev"},{"key":"60_CR33","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.amjmed.2006.11.013","volume":"120","author":"S.C. Woods","year":"2007","unstructured":"Woods SC: The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. Am J Med 2007, 120:S9\u2013S17.","journal-title":"Am J Med"},{"key":"60_CR34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1196\/annals.1367.024","volume":"1083","author":"I. Kyrou","year":"2006","unstructured":"Kyrou I, Valsamakis G, Tsigos C: The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann N Y Acad Sci 2006, 1083:270\u2013305.","journal-title":"Ann N Y Acad Sci"},{"key":"60_CR35","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.amjmed.2007.01.004","volume":"120","author":"S.C. Woods","year":"2007","unstructured":"Woods SC: Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. Am J Med 2007, 120:S19\u2013S25.","journal-title":"Am J Med"},{"key":"60_CR36","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.2337\/diabetes.54.10.2838","volume":"54","author":"S. Engeli","year":"2005","unstructured":"Engeli S, Bohnke J, Feldpausch M, et al.: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838\u20132843.","journal-title":"Diabetes"},{"key":"60_CR37","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"L.F. Gaal Van","year":"2005","unstructured":"Van Gaal LF, Rissanan AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389\u20131397.","journal-title":"Lancet"},{"key":"60_CR38","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"J.P. Despres","year":"2005","unstructured":"Despres JP, Golay A, Sjostrom L, et al.: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121\u20132134.","journal-title":"N Engl J Med"},{"key":"60_CR39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"F.X. Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006, 295:761\u2013775.","journal-title":"JAMA"},{"key":"60_CR40","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"A.J. Scheen","year":"2006","unstructured":"Scheen AJ, Finer N, Hollander P, et al.: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006, 368:1660\u20131672.","journal-title":"Lancet"},{"key":"60_CR41","doi-asserted-by":"crossref","unstructured":"Curioni C, Andre C: Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006, (4):CD006162.","DOI":"10.1002\/14651858.CD006162.pub2"},{"key":"60_CR42","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1345\/aph.1E499","volume":"39","author":"S.T. Boyd","year":"2005","unstructured":"Boyd ST, Fremming BA: Rimonabant\u2014a selective CB1 antagonist. Ann Pharmacother 2005, 39:684\u2013690.","journal-title":"Ann Pharmacother"},{"key":"60_CR43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","volume":"369","author":"R.S. Padwal","year":"2007","unstructured":"Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71\u201377.","journal-title":"Lancet"},{"key":"60_CR44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2146\/060258","volume":"64","author":"P.N. Patel","year":"2007","unstructured":"Patel PN, Pathak R: Rimonabant: a novel selective cannabinoid-1 receptor antagonist for the treatment of obesity. Am J Health Syst Pharm 2007, 64:481\u2013489.","journal-title":"Am J Health Syst Pharm"},{"key":"60_CR45","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/CIRCULATIONAHA.105.596130","volume":"114","author":"K.M. Gadde","year":"2006","unstructured":"Gadde KM, Allison DB: Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 2006, 114:974\u2013984.","journal-title":"Circulation"},{"key":"60_CR46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.104.077974","volume":"312","author":"B. Foll Le","year":"2005","unstructured":"Le Foll B, Goldberg SR: Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005, 312:875\u2013883.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-007-0060-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-007-0060-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-007-0060-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:56:18Z","timestamp":1559433378000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-007-0060-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["60"],"URL":"https:\/\/doi.org\/10.1007\/s11892-007-0060-0","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}